GlassScriptPhysician profile
Barbara Kayiira
NPI 1659074110
$10,082.54
in general payments reported to CMS, 2019-2025
21 companies · $5,434 in 2025
The $5,434 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $120 · 2024: $4,528 · 2025: $5,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,070.39 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,583.24 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,388.62 | 2024-2025 | Caplyta |
| Alkermes, INC. | $961.14 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Vanda Pharmaceuticals INC. | $936.14 | 2024-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $707.29 | 2024-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Indivior INC. | $684.67 | 2023-2025 | Sublocade, Perseris |
| E.R. Squibb & Sons, L.L.C. | $579.86 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $566.51 | 2024-2025 | Rexulti, Nuedexta, Abilify Mycite |
| Neurocrine Biosciences, INC. | $548.80 | 2024-2025 | Ingrezza |
| Corium, LLC | $471.66 | 2025 | Azstarys |
| Almatica Pharma LLC | $357.37 | 2023-2025 | Loreev Xr |
| Axsome Therapeutics, INC. | $351.05 | 2024-2025 | Auvelity |
| Lundbeck LLC | $318.74 | 2024-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $176.50 | 2025 | Qelbree |
| Braeburn INC. | $156.63 | 2024-2025 | Brixadi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $128.70 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Biogen, INC. | $71.74 | 2025 | Zurzuvae |
| Vertical Pharmaceuticals, LLC | $35.80 | 2025 | Relexxii |
| Tempus Ai, INC | $21.07 | 2025 | Tempus Pixel |
| Noven Therapeutics, LLC | $20.83 | 2024 | Xelstrym, Secuado |
| Takeda Pharmaceuticals U.S.A., INC. | $16.18 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Kayiira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.